<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03480087</url>
  </required_header>
  <id_info>
    <org_study_id>Cardiocare</org_study_id>
    <nct_id>NCT03480087</nct_id>
  </id_info>
  <brief_title>Subclinical Cardio-toxicities Evaluation With Strain Rate Echocardiography After Chemotherapy and/or Mediastinal Radiotherapy in Patient With Lymphoma</brief_title>
  <acronym>Cardiocare</acronym>
  <official_title>Subclinical Cardio-toxicities Evaluation With Strain Rate Echocardiography After Chemotherapy and/or Mediastinal Radiotherapy in Patient With Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera Città della Salute e della Scienza di Torino</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliera Città della Salute e della Scienza di Torino</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatments-related cardiotoxicity is a critical issue in long term lymphoma survivors,
      particularly at young age, and its early identification is important to prevent clinically
      relevant cardiac events. Complete echocardiographic assessment including 2-dimension global
      longitudinal strain (2D-GLS), seems to be an effective tools in detecting preclinical
      systolic changes to the cardiac function even when the ejection fraction is preserved. The
      aim of Cardiocare study is to investigate early detection of subclinical chemo and
      radiation-induced changes in left ventricular function using 2D-GLS.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2015</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Left ventricular ejection fraction (LVEF)</measure>
    <time_frame>Baseline, Change of LVEF from Baseline at 4/6 month (end of chemotherapy), Change of LVEF from Baseline at 6/8 months (end of radiotherapy - if applicable), Change of LVEF from Baseline at 9/11 months (3 months after treatment completion)</time_frame>
    <description>Left ventricular ejection fraction measured by echocardiography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Global Longitudinal Strain (GLS)</measure>
    <time_frame>Baseline, Change of GLS from Baseline at 4/6 month (end of chemotherapy), Change of GLS from Baseline at 6/8 months (end of radiotherapy - if applicable), Change of GLS from Baseline at 9/11 months (3 months after treatment completion)</time_frame>
    <description>Global Longitudinal Strain measured by strain-rate echocardiography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anthracycline cumulative dose</measure>
    <time_frame>4/6 month after baseline (end of chemotherapy)</time_frame>
    <description>Anthracycline cumulative dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T troponin</measure>
    <time_frame>Baseline, Before each chemotherapy administration, 4/6 month after baseline (end of chemotherapy), 6/8 months after baseline (end of radiotherapy - if applicable), 9/11 months after baseline (3 months after treatment completion)</time_frame>
    <description>T troponin rate</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <condition>Hodgkin Lymphoma</condition>
  <condition>Toxicity, Cardiac</condition>
  <arm_group>
    <arm_group_label>Chemotherapy alone</arm_group_label>
    <description>Patient treated with anthracycline containing chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapy plus radiotherapy</arm_group_label>
    <description>Patient treated with anthracycline containing chemotherapy followed by mediastinal radiotherapy</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patient 19-70 years old with HD or PMBCL or DLBCL requiring treatment with chemotherapy or
        chemotherapy plus mediastinal radiotherapy suitable for a strain-rate echocardiograpy
        evaluation
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;18 years

          -  Diagnosis of Hodgkin Disease (HD) or Primary Mediastinal B-cell lymphoma (PMBCL) or
             diffuse large B-cell lymphoma (DLBCL)

          -  Disease requiring treatment with anthracycline containing regimen only (cohort A) or
             anthracycline containing regimen followed by mediastinal radiotherapy (cohort B)

          -  Written informed consent

        Exclusion Criteria:

          -  Age &gt; 70 years

          -  Unable to perform anthracyline containing regimen

          -  Previous treatment with mediastinal radiotherapy

          -  Kidney failure (defined as creatinine x2 UNL) or liver failure (defined as AST and ALT
             x2 UNL)

          -  ECOG PS &gt; 2

          -  Echocardiographic acoustic windows not suitable for strain evaluation

          -  Any other conditions or situations preventing patients to sign informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lorella Orsucci, MD</last_name>
    <phone>+390116336751</phone>
    <email>lorsucci@cittadellasalute.to.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>SC Ematologia - AOU Città della salute e della Scienza di Torino</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorella Orsucci, MD</last_name>
      <phone>+390116336751</phone>
      <email>lorsucci@cittadellasalute.to.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2018</study_first_submitted>
  <study_first_submitted_qc>March 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2018</study_first_posted>
  <last_update_submitted>March 20, 2018</last_update_submitted>
  <last_update_submitted_qc>March 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliera Città della Salute e della Scienza di Torino</investigator_affiliation>
    <investigator_full_name>Lorella Orsucci, MD</investigator_full_name>
    <investigator_title>Medical doctor</investigator_title>
  </responsible_party>
  <keyword>strain-rate echocardiography</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>radiotherapy, mediastinal</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Hodgkin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Cardiotoxicity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

